Provenance Record

Well-structured News piece (830 words, within the 400-1200 News range). Clear Overview / What We Know / Background / What We Don't Know / Analysis arc. Appropriately hedged: topline-only data, undisclosed deucravacitinib PASI 100 figure, and pending full dataset are all explicitly noted in the 'What We Don't Know' section.

All 3 sources are BioSpace (biospace.com, allowlisted). All snapshots fetched with HTTP 200; uncompressed sha256 of each .html.gz matches the manifest (source-0 51eaecc4, source-1 8e0eb371, source-2 0c65a2aa). source-0 (head-to-head release): confirmed verbatim — 'More than 35% ... PASI 100 ... at week 16 - more than 2.5 times the response rate for deucravacitinib', LATITUDE Atlas (TAK-279-PsO-3004 / NCT06973291), 606 participants, zasocitinib 30 mg vs deucravacitinib 6 mg, statistical superiority on 'all key secondary endpoints, including PASI 90 ... sPGA 0', separation 'as early as week 8', 'generally well tolerated ... no new safety signals', NDA filing this fiscal year, '1-million-fold greater selectivity for TYK2', June 11 2026 dateline. Both direct quotes (Linda Stein Gold, Chinwe Ukomadu) reproduced word-for-word. source-1 (placebo/apremilast program): PASI 90 61.3%/51.9% vs placebo 5.0%/4.0%; PASI 100 33.4%/25.2% vs placebo 0.7%/1.1%; PASI 75 at week 4 16.8% vs 4.3% (LATITUDE PsO 3002) — all verbatim. source-2 (Nimbus $4B): $4 billion Nimbus Therapeutics acquisition, Jefferies '$5B by 2030' and 'best-in-class Ph3 results' / 'potential to redefine the oral psoriasis market', Sotyktu brand name — all verbatim. Rule 9/5i satisfied: every clinical number is carried by an allowlisted, fetchable BioSpace snapshot; the non-allowlisted primary Takeda.com / news.bms.com pages were correctly NOT cited.

Every clinical specific traces to a cited snapshot. Drug names and endpoints spelled verbatim throughout (zasocitinib, deucravacitinib, TYK2, PASI 100). Rule 2 check: the phrases 'only approved'/'only TYK2 inhibitor' appear in NO source; the article correctly used the softer, sourced descriptors 'already-marketed' and 'established' rather than the unsupported stronger claim. No hallucinated quotes or figures detected.

APPROVE. A clean, accurately sourced clinical News report. All claims trace verbatim to allowlisted, fetchable BioSpace snapshots; quotes are exact; drug-name spelling is correct; the head-to-head superiority claim and the >35% PASI 100 / 2.5x figures are reproduced precisely from the company release. The lone automated warning is a false positive (a word inside a direct quote). No corrections record required.